ArticleBMC cardiovascular disorders2026
Association between platelet-white cell ratio and all-cause mortality in critically ill patients with atrial fibrillation: a retrospective cohort study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial fibrillation is common in intensive care units and portends poor prognosis. The platelet-to-white blood cell ratio is an emerging inflammatory-coagulatory biomarker with prognostic value in cardiovascular diseases. This study examines the association between platelet-white cell ratio (PWR) and all-cause mortality in this high-risk population.
methodsIn this retrospective cohort study, clinical data were obtained from the MIMIC-IV database. We included adult intensive care unit (ICU) patients with a diagnosis of atrial fibrillation. The PWR was evaluated as the primary exposure, analysed both as a continuous measure and by quartiles. The primary endpoint was 28-day all-cause mortality, with secondary endpoints comprising mortality at 90 days, 180 days, and 1 year. Multivariable Cox models were used to evaluate the association between PWR and mortality, with adjustment for established confounders including demographics, comorbidity, and illness severity. Non-linearity was examined using restricted cubic splines, and subgroup analyses were conducted to evaluate the consistency of the association.
resultsThe analysis included 2,401 patients. After full adjustment, a unit increase in PWR was independently associated with a 2% decrease in the hazard of 28-day mortality (HR 0.98, 95% CI 0.97–0.99, p < 0.001). When analysed by quartiles, a significant inverse dose-response relationship was observed (P for trend < 0.001). Compared to the lowest quartile (Q1), patients in the highest PWR quartile (Q4) exhibited a substantially reduced hazard of death at 28 days (adjusted HR 0.55, 95% CI 0.43–0.72, p < 0.001). This inverse association remained statistically significant for 90-day and 180-day mortality but was absent at 1 year. The relationship was linear across the range of PWR values for 28-day (P for non-linearity = 0.213), 90-day (P for non-linearity = 0.476), and 180-day mortality (P for non-linearity = 0.377). The results were robust across all predefined subgroups, with no evidence of significant effect modification.
conclusionAmong critically ill patients with atrial fibrillation, a higher platelet-to-white blood cell ratio at ICU admission is inversely and linearly associated with short- and intermediate-term mortality, demonstrating a clear dose-response relationship. As an easily derived biomarker, PWR has potential utility for enhancing risk assessment in this clinical setting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.